◎ Sugi Atlas

Atlas / Drug / Nivolumab

Nivolumab

drug
On this page

Also known as BMS-936558BMS-986298MDX-1106MDX1106Nivolumab bmsNivolumab component of bms-986213Nivolumab component of opdualagONO-4538Opdivo

Summary

Nivolumab (CHEMBL2108738) is an approved antibody (ATC L01FF01) targeting PDCD1; indicated across 167 conditions including non-small cell lung carcinoma and melanoma; with CIViC clinical evidence for 27 variant-indication associations (e.g. CD274 Expression in melanoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: L01FF01
  • Targets: 1 (PDCD1)
  • Indications: 167 conditions
  • Clinical trials: 1,544
  • Precision-oncology evidence (CIViC): 27 variant–indication associations

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2108738
NameNivolumab
TypeAntibody
Max phase4
ATCL01FF01

Also known as: BMS-936558, BMS-986298, MDX-1106, MDX1106, Nivolumab, Nivolumab bms, Nivolumab component of bms-986213, Nivolumab component of opdualag, ONO-4538, Opdivo, NIVOLUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PDCD1programmed cell death 1 (CD279)Binding10.280%Q15116

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): PDCD1.

Top Reactome pathways

3 total, by targets touching each:

PathwayTargetsGenes
Co-inhibition by PD-11PDCD1
Potential therapeutics for SARS1PDCD1
PD-L1(CD274) glycosylation and translocation to plasma membrane1PDCD1

Dominant GO biological processes

GO termTargets
B cell apoptotic process1
adaptive immune response1
negative regulation of tolerance induction1
negative regulation of T cell mediated immune response to tumor cell1
negative regulation of B cell apoptotic process1
apoptotic process1
humoral immune response1
negative regulation of inflammatory response1
regulation of immune response1
negative regulation of immune response1
negative regulation of T cell receptor signaling pathway1
negative regulation of T cell activation1
positive regulation of T cell apoptotic process1
regulatory T cell apoptotic process1
immune system process1

Indications & clinical

Indications

167 indications (24 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
non-small cell lung carcinoma4MONDO:0005233EFO:0003060
melanoma4MONDO:0005105EFO:0000756
cutaneous melanoma4MONDO:0005012EFO:0000389
metastatic melanoma4MONDO:0005191EFO:0002617
head and neck squamous cell carcinoma4MONDO:0010150EFO:0000181
neoplasm4MONDO:0005070EFO:0000616
renal cell carcinoma4MONDO:0005086EFO:0000681
malignant pleural mesothelioma4MONDO:0005112EFO:0000770
mesothelioma4MONDO:0005065EFO:0000588
clear cell renal carcinoma4MONDO:0005005EFO:0000349
Hodgkins lymphoma4MONDO:0004952EFO:0000183
colorectal neoplasm4MONDO:0005335EFO:0004142
colorectal carcinoma4MONDO:0024331EFO:1001951
chromophobe renal cell carcinoma4MONDO:0017885EFO:0000335
colorectal adenocarcinoma4MONDO:0005008EFO:0000365
papillary renal cell carcinoma4MONDO:0017884EFO:0000640
oral cavity squamous cell carcinoma4MONDO:0004958EFO:0000199
transitional cell carcinoma4MONDO:0006474EFO:1000601
renal carcinoma4MONDO:0005206EFO:0002890
renal cell adenocarcinoma4MONDO:0005549EFO:0005708
lymphoma3MONDO:0005062EFO:0000574
brain neoplasm3MONDO:0021211EFO:0003833
breast carcinoma3MONDO:0004989EFO:0000305
sarcoma3MONDO:0005089EFO:0000691
glioblastoma3MONDO:0018177EFO:0000519
carcinoma of esophagus3MONDO:0019086EFO:0002916
hepatocellular carcinoma3MONDO:0007256EFO:0000182
squamous cell lung carcinoma3MONDO:0005097EFO:0000708
adenocarcinoma3MONDO:0004970EFO:0000228
squamous cell carcinoma3MONDO:0005096EFO:0000707
plasma cell myeloma3MONDO:0009693EFO:0001378
upper aerodigestive tract neoplasm3MONDO:0005398EFO:0004284
esophageal squamous cell carcinoma3MONDO:0005580EFO:0005922
head and neck cancer3MONDO:0005627EFO:0006859
lung adenocarcinoma3MONDO:0005061EFO:0000571
urothelial carcinoma3MONDO:0040679EFO:0008528
soft tissue sarcoma3MONDO:0018078EFO:1001968
gastric neoplasm3MONDO:0021085MONDO:0001056
brain cancer3MONDO:0001657MONDO:0001657
kidney cancer3MONDO:0002367MONDO:0002367
breast neoplasm3MONDO:0021100MONDO:0007254
lung neoplasm3MONDO:0021117MONDO:0008903
gastric adenocarcinoma3MONDO:0005036EFO:0000503
skin neoplasm3MONDO:0002531MONDO:0002898
urinary bladder neoplasm3MONDO:0004987EFO:0000294
skin carcinoma3MONDO:0002656EFO:0009259
kidney neoplasm3MONDO:0021163EFO:0003865
non-Hodgkin lymphoma2MONDO:0018908EFO:0005952
acute myeloid leukemia2MONDO:0018874EFO:0000222
small cell lung carcinoma2MONDO:0008433EFO:0000702
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
central nervous system cancer2MONDO:0002714EFO:0000326
biliary tract neoplasm2MONDO:0005304EFO:0003891
B-cell chronic lymphocytic leukemia2MONDO:0004948EFO:0000095
myelodysplastic syndrome2MONDO:0018881EFO:0000198
carcinoma2MONDO:0004993EFO:0000313
diffuse large B-cell lymphoma2MONDO:0018905EFO:0000403
Kaposi’s sarcoma2MONDO:0005055EFO:0000558
leukemia2MONDO:0005059EFO:0000565
oligodendroglioma2MONDO:0016695EFO:0000632
prostate adenocarcinoma2MONDO:0005082EFO:0000673
cervical carcinoma2MONDO:0005131EFO:0001061
ovarian carcinoma2MONDO:0005140EFO:0001075
lymphoid neoplasm2MONDO:0005157EFO:0001642
thyroid gland carcinoma2MONDO:0015075EFO:0002892
lung large cell carcinoma2MONDO:0003050EFO:0003050
nasopharyngeal neoplasm2MONDO:0005375EFO:0004252
rectal cancer2MONDO:0006519EFO:1000657
adrenal cortex carcinoma2MONDO:0006639EFO:1000796
inflammatory breast carcinoma2MONDO:0006804EFO:1000984
gliosarcoma2MONDO:0016681EFO:1001465
cutaneous neuroendocrine carcinoma2MONDO:0019210EFO:1001471
colon carcinoma2MONDO:0002032EFO:1001950
metastatic prostate carcinoma2MONDO:0004956EFO:0000196
peripheral T-cell lymphoma, not otherwise specified2MONDO:0004964EFO:0000211
germ cell tumor2MONDO:0005040EFO:0000514
osteosarcoma2MONDO:0009807EFO:0000637
dedifferentiated liposarcoma2MONDO:0020563EFO:0003085
basal cell carcinoma2MONDO:0020804EFO:0004193
endometrial carcinoma2MONDO:0002447EFO:1001512
oropharynx cancer2MONDO:0004608EFO:1001931
undifferentiated pleomorphic sarcoma2MONDO:0002142EFO:1001972
oral mucosa leukoplakia2MONDO:0004844HP:0002745
carcinoid tumor2MONDO:0005369EFO:0004243
viral pneumonia2MONDO:0006012EFO:0007541
uterine carcinosarcoma2MONDO:0006485EFO:1000613
peritoneal neoplasm2MONDO:0006901MONDO:0002087
neuroendocrine carcinoma2MONDO:0002120MONDO:0002120
salivary gland cancer2MONDO:0004669MONDO:0004669
ovarian cancer2MONDO:0008170MONDO:0008170
follicular lymphoma2MONDO:0018906MONDO:0018906
meningioma2MONDO:0016642MONDO:0020634
colonic neoplasm2MONDO:0005401MONDO:0021063
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
neoplasm of mature B-cells2MONDO:0004949EFO:0000096
leiomyosarcoma2MONDO:0005058EFO:0000564
hepatitis B virus infection2MONDO:0005344EFO:0004197
chronic hepatitis B virus infection2MONDO:0005366EFO:0004239
cholangiocarcinoma2MONDO:0019087EFO:0005221
small cell carcinoma2MONDO:0000402EFO:0008524
colon adenocarcinoma2MONDO:0002271EFO:1001949
severe acute respiratory syndrome2MONDO:0005091MONDO:0100096
glioma2MONDO:0021042MONDO:0100342
anaplastic large cell lymphoma2MONDO:0020325EFO:0003032
cervical adenocarcinoma2MONDO:0005153EFO:0001416
craniopharyngioma2MONDO:0018907EFO:1000209
carcinosarcoma2MONDO:0002928MONDO:0002928
nevoid basal cell carcinoma syndrome2MONDO:0007187MONDO:0007187
chordoma2MONDO:0008978MONDO:0008978
gastrointestinal stromal tumor2MONDO:0011719MONDO:0011719
uterine corpus cancer2MONDO:0006003EFO:0007532
malignant pancreatic neoplasm2MONDO:0009831EFO:1000359
malignant mesothelioma2MONDO:0006292EFO:1000355
paraganglioma2MONDO:0000448EFO:1000453
therapy-related myeloid neoplasm2MONDO:0006450EFO:1000575
uveal melanoma2MONDO:0006486EFO:1000616
neuroendocrine neoplasm2MONDO:0019496EFO:1001901
pancreatic ductal adenocarcinoma2MONDO:0005184MONDO:0005184
nasopharyngeal carcinoma2MONDO:0015459MONDO:0015459
rectal neoplasm2MONDO:0002165MONDO:0044937
acute lymphoblastic leukemia1MONDO:0004967EFO:0000220
chronic myeloid leukemia1MONDO:0011996EFO:0000339
neuroblastoma1MONDO:0005072EFO:0000621
triple-negative breast carcinoma1MONDO:0005494EFO:0005537
mantle cell lymphoma1MONDO:0018876EFO:1001469
retroperitoneal cancer1MONDO:0005941EFO:0007466
metastatic neoplasm1MONDO:0024883EFO:0009709
fallopian tube carcinoma1MONDO:0006206EFO:1000251
mycosis fungoides1MONDO:0009691EFO:1001051
diffuse intrinsic pontine glioma1MONDO:0006033EFO:1000026
T-cell non-Hodgkin lymphoma1MONDO:0015760MONDO:0015760
hepatitis D virus infection1MONDO:0005789EFO:0007304
Sezary syndrome1MONDO:0017844EFO:1000785
nerve sheath neoplasm1MONDO:0002547MONDO:0002547
female reproductive system neoplasm1MONDO:0021148MONDO:0021148
HIV infectious disease1MONDO:0005109EFO:0000180
Ewing sarcoma1MONDO:0012817EFO:0000174
synovial sarcoma1MONDO:0010434EFO:0001376
rhabdomyosarcoma1MONDO:0005212EFO:0002918
hepatitis C virus infection1MONDO:0005231EFO:0003047
ST-elevation myocardial infarction1MONDO:0041656EFO:0008585
primary cutaneous T-cell non-Hodgkin lymphoma1MONDO:0000607EFO:0002913
myeloid leukemia1MONDO:0004643MONDO:0004643

24 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1,544.

Phase distribution

PhaseTrials
PHASE2689
PHASE1323
PHASE1/PHASE2270
PHASE3135
Not specified61
EARLY_PHASE131
PHASE2/PHASE323
PHASE412

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06031233PHASE4RECRUITINGEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
NCT06934057PHASE4RECRUITINGCabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
NCT07028125PHASE4RECRUITINGDigital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
NCT07459543PHASE4NOT_YET_RECRUITINGA Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
NCT07504796PHASE4RECRUITINGctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
NCT02596035PHASE4COMPLETEDAn Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
NCT02626065PHASE4COMPLETEDImmune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies
NCT02982954PHASE4COMPLETEDA Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
NCT03313544PHASE4UNKNOWNEvolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1
NCT03444766PHASE4COMPLETEDStudy of Nivolumab for Advanced Cancers in India
NCT04513522PHASE4COMPLETEDA Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
NCT06116461PHASE4UNKNOWNNivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response
NCT02224781PHASE3ACTIVE_NOT_RECRUITINGDabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
NCT02339571PHASE2/PHASE3ACTIVE_NOT_RECRUITINGA Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
NCT02595944PHASE3ACTIVE_NOT_RECRUITINGNivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02632409PHASE3ACTIVE_NOT_RECRUITINGAn Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
NCT02785952PHASE3ACTIVE_NOT_RECRUITINGLung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
NCT03036098PHASE3ACTIVE_NOT_RECRUITINGStudy of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
NCT03055013PHASE3ACTIVE_NOT_RECRUITINGNivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT03141177PHASE3ACTIVE_NOT_RECRUITINGA Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03233711PHASE3ACTIVE_NOT_RECRUITINGNivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03383458PHASE3ACTIVE_NOT_RECRUITINGA Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
NCT03391869PHASE3ACTIVE_NOT_RECRUITINGNivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
NCT03470922PHASE2/PHASE3ACTIVE_NOT_RECRUITINGA Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
NCT03522246PHASE3ACTIVE_NOT_RECRUITINGA Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03576417PHASE3ACTIVE_NOT_RECRUITINGA Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck
NCT03661320PHASE3ACTIVE_NOT_RECRUITINGA Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
NCT03793166PHASE3ACTIVE_NOT_RECRUITINGImmunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
NCT03803553PHASE3RECRUITINGIdentification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
NCT03811015PHASE3ACTIVE_NOT_RECRUITINGTesting Immunotherapy Versus Observation in Patients With HPV Throat Cancer
NCT03873402PHASE3ACTIVE_NOT_RECRUITINGA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
NCT03907488PHASE3ACTIVE_NOT_RECRUITINGImmunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03937219PHASE3ACTIVE_NOT_RECRUITINGStudy of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03952585PHASE2/PHASE3ACTIVE_NOT_RECRUITINGDe-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
NCT04008030PHASE3ACTIVE_NOT_RECRUITINGA Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04025879PHASE3ACTIVE_NOT_RECRUITINGA Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT04039607PHASE3ACTIVE_NOT_RECRUITINGA Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
NCT04099251PHASE3ACTIVE_NOT_RECRUITINGEffectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
NCT04309409PHASE3ACTIVE_NOT_RECRUITINGAdjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma
NCT04444921PHASE3ACTIVE_NOT_RECRUITINGEA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

Clinical evidence (CIViC)

Variant × indication × effect (27 predictive associations from 28 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
CD274 ExpressionMelanomaSensitivity/ResponseNivolumab + PembrolizumabCIViC BEID704 +1
BRAF V600EColorectal CancerSensitivity/ResponseCetuximab + Nivolumab + EncorafenibCIViC BEID12624
CD274 ExpressionLung Non-small Cell CarcinomaSensitivity/ResponseAtezolizumab + Avelumab + Nivolumab + PembrolizumabCIViC BEID1167
CD274 ExpressionCancerSensitivity/ResponseNivolumabCIViC BEID1517
CD274 ExpressionMelanomaSensitivity/ResponseIpilimumab + NivolumabCIViC BEID1615
CD274 ExpressionLung Non-small Cell CarcinomaSensitivity/ResponseAtezolizumab + Avelumab + Pembrolizumab + Nivolumab + DurvalumabCIViC BEID4857
CD274 ExpressionLung Non-small Cell CarcinomaSensitivity/ResponsePembrolizumab + NivolumabCIViC BEID743
CD274 ExpressionNasopharynx CarcinomaSensitivity/ResponseNivolumabCIViC BEID9010
HLA-DRA EXPRESSIONSkin MelanomaSensitivity/ResponseNivolumab + Atezolizumab + PembrolizumabCIViC BEID985
KRAS MutationLung Non-small Cell CarcinomaSensitivity/ResponseAtezolizumab + NivolumabCIViC BEID4863
MSH2 Loss OR MLH1 LossCancerSensitivity/ResponseNivolumabCIViC BEID11677
PBRM1 Loss-of-functionRenal Cell CarcinomaSensitivity/ResponseNivolumab + PembrolizumabCIViC BEID7536
PBRM1 Loss-of-functionRenal Cell CarcinomaSensitivity/ResponseNivolumabCIViC BEID7584
TMB HighLung Non-small Cell CarcinomaSensitivity/ResponseNivolumabCIViC BEID12967
TMB LowMalignant MesotheliomaSensitivity/ResponseNivolumabCIViC BEID12918
B2M MutationColorectal CancerResistanceNivolumab + PembrolizumabCIViC BEID7271
DNMT3A MutationCancerResistanceAtezolizumab + Nivolumab + PembrolizumabCIViC BEID2926
PTEN MutationGlioblastomaResistanceNivolumab + PembrolizumabCIViC BEID8176
STK11 MutationLung AdenocarcinomaResistanceNivolumab + Atezolizumab + PembrolizumabCIViC BEID6441
MDM2 AmplificationCancerAdverse ResponseNivolumab + Pembrolizumab + IpilimumabCIViC BEID2916
MDM4 AmplificationCancerAdverse ResponseAtezolizumab + Nivolumab + PembrolizumabCIViC BEID2925
MDM4 EXPRESSIONCancerAdverse ResponseNivolumab + Atezolizumab + PembrolizumabCIViC BEID2917
MET Exon 14 Skipping Mutation AND CD274 OverexpressionLung Sarcomatoid CarcinomaSensitivity/ResponseNivolumabCIViC CEID11414
PMS2 K706FS*19GlioblastomaSensitivity/ResponseNivolumabCIViC CEID1214
TBXT ExpressionChordomaSensitivity/ResponseNivolumabCIViC CEID12067
EML4::ALK FusionColorectal CancerResistanceNivolumabCIViC CEID7482
ARID1A LossOvarian CancerSensitivity/ResponseAtezolizumab + Pembrolizumab + NivolumabCIViC DEID6399

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

4 molecules share ≥1 primary target. Top 4 by shared-target count:

MoleculeSourceStatusShared targets
PYRVINIUMChEMBLPhase 4 (approved)PDCD1
RIFABUTINChEMBLPhase 4 (approved)PDCD1
GefitinibPubChemApprovedPDCD1
PomalidomidePubChemApprovedPDCD1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot